Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

We want to take a moment to tell you about a graphic political ad you may have seen airing on ABC stations. The ad is for anti-abortion rights advocate and presidential candidate Randall Terry and ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...

One reason behind the drugmaker's poor performance is that investors are worried about potential competition for Keytruda, Merck's famous cancer drug, which is by far its biggest growth driver.

The pro-Trump ad with the most spending behind it during the first three weeks of October was from MAGA Inc., the leading super PAC backing the former president. It put nearly $18 million behind a ...

V940 is an investigational individualized neoantigen therapy under development in combination with Keytruda (pembrolizumab) as adjuvant treatment for resectable Stage II, IIIA or IIIB (N2 ...

In the first two weeks of October, Donald Trump and his allies directed about a third of all their spending on broadcast TV advertisements to ads about transgender health care, a significant ...